A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-segmental Vitiligo

Interventions

DRUG: GIA632
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals